In Review: the Human Services Committee met to raise bill concepts, including the Bipartisan Prescription Drug Task Force’s bill, which the committee voted to draft this concept. If you recall, this task force met in late 2024 and into 2025, resulting in delinking, a ban on spread pricing, and a fiduciary bill. PCMA successfully mitigated this bill. PCMA’s lobbyist met with Senate Chair Matt Lesser (D) after the hearing, and he claimed the bill concept was to make “technical fixes” and was not intended to push last year’s initial bill language. He then followed up with House Chair Jillian Gilchrest (D), who informed us that Sen. Lesser intends to introduce everything that did not pass last year, including delinking, a ban on spread pricing, and fiduciary. Chair Gilchrest indicated she doesn’t have an interest in doing this bill. Despite that feedback from the House Chair, we anticipate Senator Lesser will still try to push this through.

If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.